Curtis A. Hanson

Q: What Schools Are Affiliated With Curtis A. Hanson

Curtis A. Hanson is affiliated with the following schools: Medical College of Wisconsin, University of Minnesota, University of Pavia

Curtis A. Hanson's AcademicInfluence.com Rankings

Curtis A. Hanson

Philosophy

#7488

World Rank

#10709

Historical Rank

Logic

#4532

World Rank

#5841

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Curtis A. Hanson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Curtis A. Hanson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. (2011) (833)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (2014) (552)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment (2008) (456)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis (2009) (421)
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. (2011) (415)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. (2019) (412)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. (2017) (287)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera (2007) (285)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. (2015) (272)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients (2014) (269)
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML (2009) (268)
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients (2014) (259)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival (2008) (247)
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia (2003) (234)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients (2014) (231)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. (2012) (227)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia. (2016) (225)
Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia (2001) (223)
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia (2013) (219)
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. (2012) (206)
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia (2001) (193)
Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients (2013) (191)
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients (2014) (184)
One thousand patients with primary myelofibrosis: the mayo clinic experience. (2012) (183)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study (2015) (180)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis (2018) (176)
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes (2013) (173)
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32 (2010) (171)
Targeted deep sequencing in primary myelofibrosis. (2016) (163)
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients (2010) (162)
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. (2000) (161)
Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. (1992) (160)
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. (2012) (160)
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact (2014) (152)
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance (2013) (143)
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients (2011) (141)
Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. (2002) (141)
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. (2011) (138)
Demonstration of aberrant T‐cell and natural killer‐cell antigen expression in all cases of granular lymphocytic leukaemia (2003) (137)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. (2014) (135)
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. (2009) (134)
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. (2008) (130)
A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. (1998) (130)
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. (2011) (127)
Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. (1988) (126)
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic‐French Consortium Study (2014) (124)
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions (2007) (122)
Risk factors for leukemic transformation in patients with primary myelofibrosis (2008) (116)
Diagnostic utility of fluorescence in situ hybridization in mantle‐cell lymphoma (2000) (114)
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients (2012) (113)
The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. (2000) (113)
Bone marrow and peripheral blood involvement in mantle cell lymphoma (1998) (113)
How to Interpret and Pursue an Abnormal Complete Blood Cell Count in Adults (2005) (113)
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia (2010) (112)
Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera (2020) (110)
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. (2010) (107)
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. (1995) (106)
Calreticulin mutations and long-term survival in essential thrombocythemia (2014) (106)
Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls (2013) (104)
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival (2010) (103)
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera (2007) (103)
Different biology and clinical outcome according to the absolute numbers of clonal B‐cells in monoclonal B‐cell lymphocytosis (MBL) (2010) (99)
WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations (2010) (97)
Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. (2008) (97)
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia (2015) (97)
Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients (2016) (96)
WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature (2005) (96)
Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. (2011) (95)
Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. (2004) (93)
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts (2018) (92)
Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype (2010) (91)
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients (2018) (89)
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review (2014) (88)
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML (2013) (87)
Prognostic importance of T and NK‐cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia (2008) (87)
Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen. (1994) (86)
Markedly diminished epidermal keratinocyte expression of intercellular adhesion molecule-1 (ICAM-1) in Sézary syndrome. (1989) (86)
Validation of a new prognostic index for patients with chronic lymphocytic leukemia (2009) (85)
Driver mutations and prognosis in primary myelofibrosis: Mayo‐Careggi MPN alliance study of 1,095 patients (2018) (85)
Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. (1996) (84)
Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts (2008) (81)
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). (2013) (81)
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia (2000) (79)
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. (2018) (77)
Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia (2009) (76)
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk‐Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups (2019) (75)
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype (2014) (74)
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. (2008) (74)
Acute biphenotypic leukaemia: immunophenotypic and cytogenetic analysis (1993) (74)
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients (2017) (74)
Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. (1999) (73)
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912) (2018) (73)
Epstein-Barr virus--determined clonality in posttransplant lymphoproliferative disease. (1990) (73)
Common occurrence of monoclonal B‐cell lymphocytosis among members of high‐risk CLL families (2010) (73)
ASXL1 mutations are frequent and prognostically detrimental in CSF3R‐mutated chronic neutrophilic leukemia (2015) (71)
Immunohistochemical demonstration of acid phosphatase isoenzyme 5 (tartrate-resistant) in paraffin sections of hairy cell leukemia and other hematologic disorders. (1997) (71)
Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders (2007) (70)
The efficacy of ibrutinib in the treatment of Richter syndrome. (2015) (70)
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. (2011) (69)
A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome. (2006) (69)
Flow Cytometric Assessment of TCR-Vβ Expression in the Evaluation of Peripheral Blood Involvement by T-Cell Lymphoproliferative Disorders (2004) (68)
Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes (2015) (68)
The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients (2010) (68)
Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype (2009) (67)
Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. (2011) (66)
Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. (2002) (66)
Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. (2002) (65)
IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes (2011) (65)
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. (2007) (65)
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. (2011) (65)
Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course (1999) (65)
Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience (2015) (65)
Long‐term outcome of pomalidomide therapy in myelofibrosis (2012) (65)
U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions (2018) (64)
Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? (2003) (63)
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low‐risk essential thrombocythemia and polycythemia vera (2009) (62)
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma (2003) (61)
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) and the role of next‐generation sequencing (2016) (61)
Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. (2003) (61)
Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project (2014) (61)
DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia (2017) (60)
True histiocytic lymphoma: histopathologic, immunophenotypic and genotypic analysis (1989) (58)
Myelodysplasia with fibrosis: a distinct entity? (2001) (57)
Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. (2010) (57)
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. (2002) (56)
CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. (1990) (56)
Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome) (1997) (56)
An unusual case of leukemic mantle cell lymphoma with a blastoid component showing loss of CD5 and aberrant expression of CD10. (2004) (56)
Next‐generation sequencing in systemic mastocytosis: Derivation of a mutation‐augmented clinical prognostic model for survival (2016) (53)
Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome (2015) (53)
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome (2015) (53)
Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia (2016) (53)
Age and platelet count are IPSS‐independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival (2010) (52)
Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not (2009) (51)
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis (2009) (51)
Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1). (1989) (50)
Immunophenotypic attributes of benign peripheral blood gammadelta T cells and conditions associated with their increase. (2008) (50)
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome (2012) (50)
Immunophenotyping of acute myeloid leukemia using monoclonal antibodies and the alkaline phosphatase-antialkaline phosphatase technique. (1987) (49)
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)? (2008) (49)
Richter's syndrome presenting as primary central nervous system lymphoma. Transformation of an identical clone. (1990) (49)
Concurrent eosinophilic fasciitis and cutaneous T-cell lymphoma. Eosinophilic fasciitis as a paraneoplastic syndrome of T-cell malignant neoplasms? (1991) (49)
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. (2018) (49)
Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells (1997) (49)
Plasmacytoid monocyte proliferation associated with myeloproliferative disorders (1992) (48)
Therapy related‐chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML (2018) (47)
A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms (2010) (47)
Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger (2018) (46)
Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model (2019) (46)
Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part IV – postanalytic considerations (2013) (45)
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history (2015) (45)
An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. (2011) (45)
Mutations and prognosis in myelodysplastic syndromes: karyotype‐adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model (2018) (45)
Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. (1996) (44)
Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia (2015) (43)
Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL) (2013) (43)
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis (2014) (43)
Acute Lymphoblastic Leukemia with Eosinophilia (1990) (42)
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing (2016) (42)
Bone marrow manifestations of peripheral T-cell lymphoma. A study of 30 cases. (1986) (42)
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia (2017) (41)
CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. (2008) (41)
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia (2016) (41)
Identification of two related markers for common acute lymphoblastic leukemia as heat shock proteins. (1990) (41)
Momelotinib therapy for myelofibrosis: a 7-year follow-up (2018) (40)
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea (2008) (39)
Incidence of chronic lymphocytic leukemia and high‐count monoclonal B‐cell lymphocytosis using the 2008 guidelines (2014) (39)
Immnuophenotypic and Gene Expression Analysis of Monoclonal B Cell Lymphocytosis Shows Biologic Characteristics Associated With Good Prognosis CLL (2011) (39)
True histiocytic lymphoma. (1991) (39)
Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance (2016) (39)
Chromosome 8p11.2 translocations: Prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution (2010) (38)
Acute myeloid leukemia with minimal differentiation. A multiple parameter study. (1998) (37)
Anti-CD34 immunoperoxidase staining in paraffin sections of acute leukemia: comparison with flow cytometric immunophenotyping. (1992) (37)
Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients (2010) (37)
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre (2018) (37)
Simultaneous Lymphocyte Predominant Hodgkin's Disease and Large‐Cell Lymphoma (1991) (37)
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental (2018) (36)
20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis (2008) (36)
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness (2018) (36)
Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients (2018) (36)
Leukemia risk models in primary myelofibrosis: an International Working Group study (2012) (36)
CD5‐positive chronic B‐cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity (2010) (35)
Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients (2018) (35)
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. (2019) (35)
Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis (2014) (35)
Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. (1998) (35)
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes (2013) (34)
Induction of Malignant Plasma Cell Proliferation by Eosinophils (2013) (34)
Monocytosis in polycythemia vera: Clinical and molecular correlates (2016) (34)
Flow cytometric measurement of hemoglobin F in RBCs: diagnostic usefulness in the distinction of hereditary persistence of fetal hemoglobin (HPFH) and hemoglobin S-hPFH from other conditions with elevated levels of hemoglobin F. (2002) (34)
Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia (2010) (34)
Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. (2010) (34)
S100-positive, T-cell chronic lymphoproliferative disease: an aggressive disorder of an uncommon T-cell subset. (1991) (34)
Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons (2016) (33)
NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis (2006) (32)
Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era (2008) (32)
A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients (2014) (32)
Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells (2015) (32)
Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. (2011) (31)
CD30 (Ki‐1)‐positive, anaplastic large cell lymphoma mimicking gastrointestinal carcinoma (1992) (31)
CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value (2016) (30)
Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells. (1996) (30)
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial (2022) (30)
Immunophenotypic aberrancy in adult acute lymphoblastic leukemia. (1990) (30)
Chronic active Epstein-Barr virus infection and virus-associated hemophagocytic syndrome. (1991) (30)
Efficacy of fluorescence in situ hybridization for detecting PML/RARA gene fusion in treated and untreated acute promyelocytic leukemia. (1994) (29)
Eosinophilic leukemia: a myeloproliferative disorder distinct from the hypereosinophilic syndrome. (1991) (29)
Detection of Philadelphia chromosome-positive cells from glass slide smears using the polymerase chain reaction. (1990) (29)
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases (2021) (29)
Severe vitamin B12 deficiency resulting in pancytopenia, splenomegaly and leukoerythroblastosis (2008) (29)
Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma. (1994) (29)
Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis (2018) (28)
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms (2009) (28)
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia (2010) (28)
Detection of Epstein-Barr virus genome in Ki-1 (CD30)-positive, large-cell anaplastic lymphomas using the polymerase chain reaction. (1992) (28)
Genotypic analysis of T-cell clones derived from cutaneous T-cell lymphoma lesions demonstrates selective growth of tumor-infiltrating lymphocytes. (1990) (28)
Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets (2010) (28)
Sole abnormalities of chromosome 7 in myeloid malignancies: Spectrum, histopathologic correlates, and prognostic implications (2012) (28)
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. (2012) (28)
Mapping studies and expression of genes located on human chromosome 11, band q23. (1988) (28)
Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. (2011) (27)
Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis (2018) (27)
CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. (2010) (27)
The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years. (2011) (27)
Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates (2010) (27)
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis (2015) (26)
Fine-needle aspiration and immunophenotyping. A role in diagnostic hematopathology? (1994) (26)
Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization (2001) (26)
Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance (2017) (26)
MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. (2010) (26)
JAK2 exon 12 mutated polycythemia vera: Mayo‐Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease (2018) (25)
Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations (2016) (25)
Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis (2018) (25)
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis (2017) (25)
Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases (2018) (25)
ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis (2015) (24)
Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients (2011) (24)
The expression of the novel cytotoxic protein granzyme M by large granular lymphocytic leukaemias of both T‐cell and NK‐cell lineage: an unexpected finding with implications regarding the pathobiology of these disorders (2007) (24)
Identification of a cellular polypeptide that distinguishes between acute lymphoblastic leukemia in infants and in older children. (1989) (24)
Blast Phase Chronic Myelomonocytic Leukemia: Mayo-MDACC Collaborative study of 171 cases (2018) (23)
CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia (2017) (23)
Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. (1997) (23)
Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis (2013) (23)
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. (2018) (23)
Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients (2017) (22)
Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice (2015) (22)
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information (2018) (22)
Cytogenetic findings in WHO‐defined polycythaemia vera and their prognostic relevance (2018) (22)
Presence and expression of human herpesvirus 6 in peripheral blood mononuclear cells of S100-positive, T cell chronic lymphoproliferative disease. (1995) (22)
MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia (2016) (22)
Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients. (2016) (21)
Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population (2012) (21)
Virus-associated hemophagocytic syndrome following bone marrow transplantation. (1991) (21)
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival (2018) (21)
Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. (2008) (21)
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia (2010) (21)
Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis (2013) (20)
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone (2018) (20)
Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study (2017) (20)
Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi‐institutional study (2016) (20)
Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment (2015) (20)
Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients (2010) (19)
Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients (2017) (19)
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis (2016) (19)
Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis (2017) (19)
Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision‐making in otherwise low or intermediate‐1 risk patients with myelofibrosis (2018) (19)
Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. (2001) (19)
Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. (2008) (18)
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. (2018) (18)
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts (2018) (18)
Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms (2014) (18)
Lineage switch in Philadelphia chromosome‐ positive acute lymphoblastic leukemia (1994) (18)
Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study, (2011) (18)
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. (2010) (18)
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience (2015) (18)
BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. (2016) (18)
Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations (2016) (18)
Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory‐specific incidence and prognostic impact among 348 informative cases (2018) (17)
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. (2009) (17)
Follicular lymphoma with involvement of the splenic marginal zone: a pitfall in the differential diagnosis of splenic marginal zone cell lymphoma. (1996) (17)
Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. (2009) (17)
Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. (2016) (17)
Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. (2015) (17)
Lymphocytic infiltrates of the skin in association with cyclosporine therapy. (1990) (17)
Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q) (2017) (17)
Epstein-Barr virus and bcl-2 protein overexpression are not detected in the neoplastic cells of nodular lymphocyte predominance Hodgkin's disease. (1995) (16)
Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. (2015) (16)
Monoclonal B-cell lymphocytosis: definitions and natural history (2009) (16)
Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL) (2020) (16)
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes (2013) (16)
A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. (2013) (16)
The Prognostic Significance of Trisomy 8 in Patients With Acute Myeloid Leukemia (2002) (16)
The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences? (2009) (16)
Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine–phenotype study (2013) (15)
Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. (2015) (15)
MPL-mutated essential thrombocythemia: a morphologic reappraisal (2018) (15)
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG‐ACRIN cancer research group (E1908) (2016) (15)
FIBROADENOMATOSIS (FIBROADENOMATOID MASTOPATHY): A BENIGN BREAST LESION WITH COMPOSITE PATHOLOGIC FEATURES (1987) (15)
Erratum: Chronic myelomonocytic leukemia in younger patients: Molecular and cytogenetic predictors of survival and treatment outcome (Blood Cancer Journal (2015) 5 (e280) DOI: 10.1038/bcj.2015.9) (2015) (14)
Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis (2018) (14)
IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes (2019) (14)
Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. (2008) (14)
Cytoimmunologic monitoring and heart transplantation. (1988) (14)
Mutations and thrombosis in essential thrombocythemia (2021) (14)
Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis (2018) (13)
Concurrent activating KIT mutations in systemic mastocytosis (2016) (13)
Flow cytometric analysis of cytologic specimens in hematologic disease (1989) (13)
A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy (2018) (13)
The ( 11 ; 14 ) ( q 13 ; q 32 ) Translocation in Multiple Myeloma A Morphologic and Immunohistochemical Study (2002) (13)
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. (2016) (12)
Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia (2015) (12)
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib. (2021) (12)
Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates (2017) (12)
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL) (2019) (12)
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts (2014) (12)
Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. (2018) (11)
U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates (2018) (11)
The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia (2017) (11)
Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings (2017) (11)
Use of the Optum Labs Data Warehouse To Assess Test Ordering Patterns for Diagnosis of Helicobacter pylori Infection in the United States (2015) (11)
A modified method of DNA extraction from peripheral blood and bone marrow specimens (1988) (11)
Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study (2014) (11)
The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly‐annotated patients with primary myelofibrosis (2018) (11)
Detection and classification of acute leukemia by the Coulter STKS Hematology Analyzer. (1996) (11)
Platelet count is an IPSS‐independent risk factor predicting survival in refractory anaemia with ringed sideroblasts (2008) (10)
Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates (2018) (10)
Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families. (2020) (10)
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab (2013) (10)
The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL (2021) (10)
Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders (2007) (10)
Therapy-Related Myeloid Neoplasms. (2015) (10)
Kappa light chain gene rearrangement in T-cell acute lymphoblastic leukemia. (1990) (10)
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method (2019) (10)
Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q. (2006) (10)
Renal Disease In Patients With Chronic Lymphocytic Leukemia (CLL) (2013) (10)
Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value. (2012) (9)
The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. (2020) (9)
Independent Validation of the MD Anderson Cancer Center Risk Model for Myelodysplastic Syndromes (MDS), and Comparison to the International Prognostic Scoring System (IPSS) and the World Health Organization-Based Prognostic Scoring System (WPSS). (2009) (9)
Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis (2008) (9)
Erratum: Molecular correlates of anemia in primary myelofibrosis: A significant and independent association with U2AF1 mutations (Blood Cancer Journal (2016) 6 (e415) DOI: 10.1038/bcj.2016.22) (2016) (9)
Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. (2015) (9)
20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long‐lived patients (2018) (9)
Trisomy 8 in acute myeloid leukemia (2000) (8)
P089 Is idiopathic cytopenia of undetermined significance (ICUS) a valid clinical concept? A longitudinal clinicopathological study (2009) (8)
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia (2021) (8)
Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome (2013) (8)
World Health Organization class-independent risk categorization in mastocytosis (2019) (8)
Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival (2016) (8)
Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection (2010) (8)
Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study (2014) (8)
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia (2016) (8)
Young platelet millionaires with essential thrombocythemia (2021) (8)
Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL, (2011) (8)
Characterization of a new human multiple myeloma cell line, UMJF-2, which suppresses antibody production by B-lymphocytes in vitro. (1991) (7)
Splenomegaly and thrombosis risk in essential thrombocythemia: the mayo clinic experience (2016) (7)
Identification of a restriction fragment length polymorphism involving the oncogene ETS-1 on chromosome 11q23 (1987) (7)
Independent Validation of the 2008 World Health Organization (WHO) Reclassification of Myelodysplastic Syndromes (MDS) Associated with Ring Sideroblasts (2008) (7)
Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib (2022) (7)
Not all CALR mutations are created equal (2015) (7)
Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis (2018) (7)
A case of hairy cell leukemia with CCND1-IGH@ translocation: indolent non-nodal mantle cell lymphoma revisited. (2011) (7)
Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL (2011) (7)
Extreme thrombocytosis in low‐risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies (2021) (7)
A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience (2018) (7)
Trisomy 11: prevalence among 22 403 unique patient cytogenetic studies and clinical correlates (2010) (7)
Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. (2008) (6)
The role of 18F-FDG-PET in detecting Richter transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor (2020) (6)
Low JAK2 V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival. (2007) (6)
Acute promyelocytic leukemia with t(15;16;17;19) and unusual fluorescence in situ hybridization pattern with PML and RARA probes. (1996) (6)
Bone Marrow Biopsy Operator Experience and Impact on Aspirate, Biopsy, and Ancillary Testing Quality (2018) (6)
Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms. (2014) (6)
Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis. (2007) (6)
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans (2021) (6)
Myelodysplastic syndrome and the patient with unexplained cytopenias. (1997) (6)
Chronic Eosinophilic Leukemia—Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma (2013) (6)
The 2016 revised World Health Organization definition of ‘myelodysplastic syndrome with isolated del(5q)’; prognostic implications of single versus double cytogenetic abnormalities (2017) (6)
Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data (2021) (6)
Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases (2022) (6)
Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV) (2018) (5)
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases (2021) (5)
Association of a mature B cell leukemia with a 4p+ chromosomal abnormality: derivation and characterization of a cell line. (1989) (5)
Is It Time for a New Gold Standard? FISH vs Cytogenetics in AML Diagnosis. (2016) (5)
for acute myeloid leukemia predicts superior relapse-free survival Early peripheral blood blast clearance during induction chemotherapy (2013) (5)
Liver function test abnormalities and their clinical relevance in primary myelofibrosis (2017) (5)
Presence of Immunoglobulin Heavy Chain Gene (IGH) Translocations in Chronic Lymphocytic Leukemia Is Related to Poor Prognosis. (2007) (5)
Epstein-Barr-virus-related post-bone-marrow-transplant lymphoproliferative disease: association with cytomegalovirus infection and Down syndrome donor marrow. (1989) (5)
T cell receptor β-chain gene rearrangement without γ-chain gene rearrangement in cutaneous T cell lymphoma: An unusual finding (1990) (5)
Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? (2022) (5)
Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates (2018) (5)
Applications of flow cytometry in diagnostic pathology. (1989) (5)
Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide (2018) (5)
Marrow fibrosis associated with a Philadelphia chromosome. (1992) (5)
Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series (2016) (5)
20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients (2018) (4)
Abstract 2287: Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Olmsted county, 2000-2010: impact of the 2008 International Workshop on CLL Guidelines. (2013) (4)
Quest for quality: department of laboratory medicine and pathology, Mayo Clinic. (2004) (4)
Mayo Clinic experience with 1123 adults with acute myeloid leukemia (2021) (4)
Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus (2012) (4)
Progression and Survival of Monoclonal B-cell Lymphocytosis (MBL): A screening study of 10,139 individuals. (2022) (4)
The Prognostic Importance of T and NK-Cells in a Consecutive Series of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia. (2007) (4)
Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q (2009) (4)
Clinical Applications of Molecular Biology in Diagnostic Hematopathology (1993) (4)
The clinical and laboratory approach to the CD5/CD10 negative B‐cell chronic lymphoproliferative leukemias (2008) (4)
Hematological diseases: prototypical conditions requiring the diagnostic and prognostic use of molecular data. (2013) (4)
Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis (2016) (4)
Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations (2016) (4)
A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (2019) (4)
Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts (2011) (4)
Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL (2010) (4)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis (2011) (4)
Real-World “myelodysplastic Syndrome-unclassifiable” and Its Comparison With “refractory Cytopenia With Multi-Lineage dysplasia” and “refractory anemia” (2013) (3)
Revised Cytogenetic Risk Stratification in Primary Myelofibrosis: A Mayo Clinic Study of 903 Patients (2014) (3)
B-cell prolymphocytic leukemia has 3 subsets. (2019) (3)
DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status (2010) (3)
Molecular Prognostic Factors and Outcome among a Cohort of Patients with Monoclonal B-Cell Lymphocytosis (MBL). (2007) (3)
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy (2021) (3)
Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank (2021) (3)
Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis (2013) (3)
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia (2021) (3)
Proliferative Versus Dysplastic Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates (2016) (3)
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm (2022) (3)
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients (2016) (3)
MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis (2017) (3)
Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy. (2009) (3)
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3‐ITD mutational status (2018) (3)
ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance (2015) (3)
Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia (2015) (2)
Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study (2018) (2)
A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count (2021) (2)
Molecular Correlates of Anemia in Primary Myelofibrosis (2015) (2)
Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis (2018) (2)
Clonal cytogenetic anomalies suggestive of a myelodysplastic syndrome in patients with morphologically normal bone marrow aspirates (2000) (2)
MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial (2021) (2)
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome (2015) (2)
Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients, (2011) (2)
Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies (2019) (2)
Impact of an electronic decision support rule on ESR/CRP co-ordering rates in a community health system and projected impact in the tertiary care setting and a commercially insured population. (2019) (2)
European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response (2022) (2)
Serial cerebrospinal fluid examinations to diagnose hematological malignancy causing neurological disease (2016) (2)
Central Nervous System Involvement By Chronic Lymphocytic Leukemia (2015) (2)
Progression and survival of MBL: a screening study of 10 139 individuals (2022) (2)
Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution. (2007) (2)
Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families. (2009) (2)
3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups (2018) (2)
Genetic predictors of response to specific drugs in primary myelofibrosis (2018) (2)
Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates (2016) (2)
A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) (2011) (2)
Pregnancy in patients with myelofibrosis: Mayo–Florence series of 24 pregnancies in 16 women (2021) (2)
Influence of Age at Diagnosis On Utility of Prognostic Testing in Patients with CLL. (2009) (2)
Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies (2018) (2)
Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide (2013) (2)
The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) (2013) (2)
Immunophenotyping of hematologic malignant conditions: to flow or not to flow? (1991) (2)
Practice‐relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm (2018) (2)
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib (2022) (2)
Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases (2018) (2)
Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL) (2014) (2)
Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates (2016) (2)
Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings (2016) (1)
Abstract 650: MCIR1: A patient-derived ibrutinib-resistant mantle cell lymphoma line for the study of ibrutinib resistance and drug discovery (2020) (1)
ASXL1 and SETBP1 Mutations and Their Prognostic Contribution in Chronic Myelomonocytic Leukemia: An International Study of 466 Patients (2015) (1)
Peripheral Blood JAK2V617F Quantitative Assessment in Clinical Practice: Correlations Between Allele Burden and Clinical Phenotype (2015) (1)
JAK2 Exon 12 Mutated Polycythemia Vera: The Mayo Clinic-University of Florence Experience with 33 Consecutive Cases and Comparison with JAK2 V617F Mutated Disease (2017) (1)
In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics (2011) (1)
Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms (2021) (1)
Revisiting the need for bone marrow examination in chronic myeloid leukemia (2018) (1)
ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients (2013) (1)
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts (2018) (1)
Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes (2011) (1)
Abstract B02: The Akt inhibitor MK-2206 in combination with rituximab and bendamustine demonstrates efficacy in relapsed/refractory chronic lymphocytic leukemia: Updated results from the NCCTG N1087 Alliance study (2015) (1)
MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance (2021) (1)
Early Thrombotic Events Following Splenectomy for Myelofibrosis: Incidence, Risk Factors and Effect of Pre-Emptive Anticoagulant Therapy (2017) (1)
IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes, (2011) (1)
Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype (2010) (1)
CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity. (2008) (1)
Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis (2022) (1)
IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis. (2009) (1)
Leukocytosis at Diagnosis and the Risk of Subsequent Thrombosis in Low-Risk Essential Thrombocythemia and Polycythemia Vera. (2008) (1)
The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes (2018) (1)
The Natural History of CSF3R-Mutated Chronic Neutrophilic Leukemia: A Mayo Clinic Series of 14 Consecutive Cases (2014) (1)
Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? (2022) (1)
Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients (2012) (1)
Neither Serum Ferritin Nor Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts. (2007) (1)
Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases (2016) (1)
Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed? (2018) (1)
PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT and Promising Surrogate Marker for Clonal Relatedness (2017) (1)
DNA fragments of altered electrophoretic mobility in leukemia samples can arise from double-strand DNA breaks at nuclease hypersensitive sites of active genes. (1993) (1)
Lymphoid Malignancy: Immunocytology and Cytogenetics (1991) (1)
Clonal Evolution In Patients With Previously Untreated Chronic Lymphocytic Leukemia (2013) (1)
Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population (2010) (1)
Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis (2015) (1)
CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value (2015) (1)
The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis (2018) (1)
Atypical case presentation of Zieve's syndrome (2013) (1)
Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival (2013) (1)
The prognostic significance of del6q23 in chronic lymphocytic leukemia (2021) (1)
A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival (2015) (1)
U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis (2016) (1)
Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients (2016) (1)
Tumors of the Bone Marrow (1995) (0)
The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis (2019) (0)
blasts defined myelodysplastic syndromes without excess - Organization Prognostic irrelevance of ring sideroblast percentage in World Health (2013) (0)
Abstract #96: Confirmation of a set of genetic susceptibility variants for chronic lymphocytic leukemia (CLL) (2009) (0)
5.11 Lenalidomide Consolidation Seems to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated Chronic Lymphocytic Leukemia (2011) (0)
Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model (2019) (0)
MPL-mutated essential thrombocythemia: a morphologic reappraisal (2018) (0)
A Clinicopathologic Study of 107 (2015) (0)
Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes (2016) (0)
1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience (2018) (0)
1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events (2022) (0)
Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed? (2018) (0)
U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia (2013) (0)
3.12 The Prevalence of Serious Infections in a Community-Based Cohort of Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study (2011) (0)
3.13 Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Community-based Cohort Study of Newly Diagnosed Patients Compared to Controls (2011) (0)
Prevalence of MBL Increases Over Time In Relatives of CLL Families (2011) (0)
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis (2022) (0)
Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis (2018) (0)
Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations (2015) (0)
Prevalence of erythrocyte hemoglobin H inclusions in unselected patients with myelodysplastic syndromes or myeloproliferative disorders (2007) (0)
Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis (2018) (0)
Blast Transformation in Chronic Myelomonocytic Leukemia: Risk Factors and Outcome (2014) (0)
Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices (2015) (0)
Identification of a restriction fragment length polymorphism involving the oncogene ETS-1 on chromosome 11q23. (1987) (0)
Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology. (2009) (0)
Revised DIPSS-Plus: A Composite Clinical, Cytogenetic and Molecular Prognostic System for Primary Myelofibrosis (2017) (0)
Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases (2021) (0)
Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia (2020) (0)
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival (2018) (0)
Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis (2018) (0)
Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS) (2012) (0)
Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients (2013) (0)
Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia (2016) (0)
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental (2018) (0)
General Overview of Chronic Lymphoproliferative Disorders: Morphologic and Immunophenotypic Analysis (1993) (0)
Momelotinib therapy for myelofibrosis: a 7-year follow-up (2018) (0)
T cell receptor beta-chain gene rearrangement without gamma-chain gene rearrangement in cutaneous T cell lymphoma: an unusual finding. (1990) (0)
The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities (2016) (0)
Association of CD49d expression with small lymphocytic lymphoma (SLL) presentation of chronic lymphocytic leukemia (CLL). (2016) (0)
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study (2014) (0)
Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R (2016) (0)
Treatment Free Survival of Patients with MBL and Early CLL: Follow-up of 405 Patients at Mayo Clinic. (2008) (0)
Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes (2020) (0)
Single Case Reports Kappa Light Chain Gene Rearrangement in T-Cell Acute Lymphoblastic Leukemia (2016) (0)
Abstract 5256: Incidence of squamous cell carcinoma (SCC) in a large screening cohort of monoclonal B-cell lymphocytosis (MBL) (2022) (0)
Relationship among three common hematological premalignant conditions. (2023) (0)
Myelodysplastic/Myeloproliferative Diseases (Overlap Syndromes) (2007) (0)
Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients (2014) (0)
Genetic predictors of response to specific drugs in primary myelofibrosis (2018) (0)
Poster: CLL-506 Clinical Outcomes Beyond Progression on Ibrutinib in Patients With Chronic Lymphocytic Leukemia (2022) (0)
Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older (2020) (0)
A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy (2019) (0)
Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory) (2021) (0)
Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events (2018) (0)
Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera (2016) (0)
The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events (2021) (0)
1102 PRE-EXISTING OR INTRA-OPERATIVELY DISCOVERED MALIGNANT LYMPHOMA AT THE TIME OF RADICAL PROSTATECTOMY IS ASSOCIATED WITH LOWER OVERALL SURIVAL WITHOUT CHANGE IN CANCER SPECIFIC SURVIVAL (2011) (0)
Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status. (2009) (0)
Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions (2021) (0)
Abstract 3256: The prevalence of non-chronic lymphocytic leukemia (CLL) phenotype monoclonal B-cell lymphocytosis (MBL) in a population-based cohort of U.S. adults (2018) (0)
World Health Organization class-independent risk categorization in mastocytosis (2019) (0)
Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger (2018) (0)
Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q) (2017) (0)
The changing field of hematopathology. Tradition versus technology. (1990) (0)
3.2 Evolution of High-Sensitivity, Multi-Color Flow Cytometric Immunophenotyping for Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia: Peripheral Blood versus Bone Marrow? (2011) (0)
Abstract 1853: Monoclonal B-cell Lymphocytosis (MBL) has increased incidence in non-Hodgkin lymphoma (NHL) Families (2010) (0)
Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's Syndrome): Large Retrospective Analysis From a Single Institution. (2012) (0)
DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia (2016) (0)
152 BONE MARROW CONVENTIONAL KARYOTYPING AND FLUORESCENCE IN SITU HYBRIDIZATION (FISH): DEFINING AN EFFECTIVE UTILIZATION STRATEGY FOR THE EVALUATION OF MYELODYSPLASTIC SYNDROME (MDS) (2015) (0)
Incidence of Autoimmunity in Patients (pts) with Low-Risk (LR) Myelodysplastic Syndrome (MDS): 10 Years Follow-up (2012) (0)
Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients (2013) (0)
Circulating blasts or myeloid precursor cells in peripheral blood can predict success of cytogenetic analysis. (2009) (0)
Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients (2018) (0)
Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis (2012) (0)
The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis (2012) (0)
Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci (2010) (0)
Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases (2018) (0)
Isolated Trisomy 8 in the Myelodysplastic Syndromes. (2009) (0)
Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years. (2009) (0)
Rapid Communication Detection of Philadelphia Chromosome-positive Cells from Glass Slide Smears Using the Polymerase Chain Reaction (2007) (0)
Whole Arm Duplication of 1q in Myeloid Neoplasm, with Emphasis On Derivative (1;7)(q10;p10). (2009) (0)
Calculator‐free point‐of‐care prognostication in myelodysplastic syndromes (2019) (0)
The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia (2016) (0)
expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization (2013) (0)
Clonal Rearrangementfor Imnmunoglobulin and T-Cell Receptor Genes in Systemic Castleman's Disease Association With Epstein-Barr Virus (2007) (0)
Splanchnic Vein Thrombosis in Overt Myeloproliferative Neoplasms: The Mayo Clinic Experience with 107 Unselected Consecutive Cases (2017) (0)
Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS) (2018) (0)
3.15 Prevalence of MBL Increases over Time in Relatives of CLL Families (2011) (0)
Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2 -Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases (2017) (0)
Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution (2008) (0)
Correlation of CD20 fluorescence intensity with morphologic parameters in B-cell chronic lymphoproliferative disorders (1994) (0)
CLL-506 Clinical Outcomes Beyond Progression on Ibrutinib in Patients With Chronic Lymphocytic Leukemia. (2022) (0)
Red Blood Cell Transfusion Requirement at Diagnosis Adversely Affects Both Overall and Leukemia-Free Survival in Primary Myelofibrosis - Increased Serum Ferritin or Total Transfusion Burden Does Not (2008) (0)
Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912 (2021) (0)
Book Review: Blood Cell Morphology: Grading Guide (2010) (0)
European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response (2022) (0)
Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? (2022) (0)
Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T) (2015) (0)
Diagnostic Role of Lumbar Puncture (LP) for the diagnosis of Central Nervous System (CNS) Involvement by Chronic Lymphocytic Leukemia(CLL)/Richter Syndrome (RS) (2015) (0)
Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome (2014) (0)
Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020 (2021) (0)
Erratum: Conventional karyotyping and fluorescence in situ hybridization:An effective utilization strategy in diagnostic adult acute myeloid leukemia. (American Journal of Clinical Pathology (2015) 143 (873-878)) (2015) (0)
8p11.2 Translocations: Prevalence, FISH Analysis for FGFR1 and MYST3, and Clinicopathologic Correlates in a Consecutive Cohort of 13 Cases From a Single Institution. (2009) (0)
Deletion 5q in WHO-Defined Myeloproliferative Neoplasms: A Clinicopathological Description. (2007) (0)
CD 1 IC ( LEU-M 5 ) Expression Characterizes a B-Cell Chronic Lymphoproliferative Disorder With Features of Both Chronic Lymphocytic Leukemia and Hairy Cell Leukemia (2003) (0)
Abstract 655: Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (MFC) vs. FISH (2018) (0)
The Anatomy of Recurrent Thrombosis and Its Risk Factors in Myeloproliferative Neoplasms (2017) (0)
Abstract 5222: Genetic variants associated with progression from monoclonal B-cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL) (2023) (0)
Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival (2022) (0)
The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study (2011) (0)
Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival (2015) (0)
Flow cytometric analysis of cytologic specimens in hematologic disease Presented in part before the International Academy of Pathology, Washington, D.C., February 28-March 3, 1988 (Lab Invest 1988; S8:37A). (1989) (0)
CLL-376: Clinical Characteristics and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL), 80 Years of Age or Older (2021) (0)
Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates (2018) (0)
Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts. (2012) (0)
Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia (2016) (0)
Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes (2016) (0)
Dr. Ayalew Tefferi of Mayo discusses December Mayo Clinic Proceedings article on primary myelofibrosis (2009) (0)
Abstract 1423: The addition of bevacizumab to chemoimmunotherapy prolongs progression-free survival in patients with chronic lymphocytic leukemia (CLL) through modulation of the microenvironment (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Curtis A. Hanson?

Curtis A. Hanson is affiliated with the following schools:

Medical College of Wisconsin
University of Minnesota
University of Pavia

Curtis A. Hanson's Academic­Influence.com Rankings

Why Is Curtis A. Hanson Influential?

Curtis A. Hanson's Published Works

Published Works

What Schools Are Affiliated With Curtis A. Hanson?

Curtis A. Hanson's AcademicInfluence.com Rankings